Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491218 | 0.90 | MAPT (0.41) | LMNAALOX5APFEN1PTGDR2TP53 | |
| SCHEMBL18908815 | 0.89 | IL1B (0.44) | LMNAALOX5APFEN1PTGDR2IL1B | |
| SCHEMBL18908796 | 0.84 | ALOX5AP (0.43) | ALOX5APFEN1PTGDR2DDR1 | |
| SCHEMBL17664477 | 0.83 | SCN9A (0.41) | LMNAALOX5APFEN1PTGDR2DDR1 | |
| SCHEMBL18908816 | 0.77 | MPL (0.48) | LMNAALOX5APFEN1TP53THRB | |
| SCHEMBL18908785 | 0.77 | LMNA (0.39) | LMNAPTGDR2TP53MAOAIL1B | |
| SCHEMBL19427332 | 0.76 | DDR1 (0.37) | LMNAALOX5APFEN1PTGDR2TP53 | |
| SCHEMBL19501577 | 0.76 | ALOX5AP (0.39) | ALOX5APFEN1PTGDR2DDR1 | |
| SCHEMBL18843187 | 0.75 | ALOX5AP (0.40) | ALOX5APFEN1PTGDR2ALPLDDR1 | |
| SCHEMBL18785058 | 0.75 | ALOX5AP (0.49) | ALOX5APFEN1PTGDR2DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202761-B1 | PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-9924719-B2 | Pyridazine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9924719-B2 | Pyridazine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20170295787-A1 | PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170295787-A1 | PYRIDAZINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
| EP-3202761-A1 | PYRIDAZINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017090655-A1 | PEST CONTROL COMPOSITION AND USE THEREOF | 住友化学株式会社 | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295787-A1 | PYRIDAZINE COMPOUND | C5, C3AR1, H1-3 | LMNA 2797/4885ALOX5AP 3627/4885FEN1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.